Amphetamine aspartate
Adderall, Amphetamine / Amphetamine / Dextroamphetamine / Dextroamphetamine, Mydayis (amphetamine aspartate) is a small molecule pharmaceutical. Amphetamine aspartate was first approved as Adderall 10 on 1996-02-13. It is used to treat attention deficit disorder with hyperactivity and narcolepsy in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Combinations
Adderall, Dextroamp saccharate, amp aspartate, dextroamp amp, Dyanavel, Mydayis (discontinued: Adderall, Dextroamp saccharate, amp aspartate, dextroamp amp, Dextroamp saccharate,amp aspartate,dextroamp amp)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Amphetamine aspartate
+
Amphetamine sulfate
+
Dextroamphetamine saccharate
+
Dextroamphetamine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ADDERALL XR 10 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD |
| ADDERALL XR 20 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD |
| ADDERALL XR 30 | Takeda | N-021303 RX | 2001-10-11 | 1 products, RLD, RS |
| ADDERALL XR 25 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
| ADDERALL XR 5 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
| ADDERALL XR 15 | Takeda | N-021303 RX | 2002-05-22 | 1 products, RLD |
| MYDAYIS | Takeda | N-022063 RX | 2017-06-20 | 4 products, RLD, RS |
Show 7 discontinued
Amphetamine
+
Amphetamine aspartate
+
Dextroamphetamine sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DYANAVEL XR | Tris Pharma | N-208147 RX | 2015-10-19 | 1 products, RLD, RS |
| DYANAVEL XR 5 | Tris Pharma | N-210526 RX | 2021-11-04 | 1 products, RLD |
| DYANAVEL XR 10 | Tris Pharma | N-210526 RX | 2021-11-04 | 1 products, RLD |
| DYANAVEL XR 15 | Tris Pharma | N-210526 RX | 2021-11-04 | 1 products, RLD |
| DYANAVEL XR 20 | Tris Pharma | N-210526 RX | 2021-11-04 | 1 products, RLD, RS |
Labels
FDA
EMA
Show 7 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| narcolepsy | HP_0030050 | D009290 | G47.4 |
| attention deficit disorder with hyperactivity | EFO_0003888 | D001289 | F90 |
Agency Specific
FDA
EMA
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
209 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | 7 | 17 | 11 | 16 | 15 | 61 |
| Hyperkinesis | D006948 | HP_0000752 | — | 5 | 11 | 9 | 10 | 11 | 42 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 3 | 12 | 5 | 1 | 17 | 35 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | 7 | 2 | 3 | 12 | 24 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | — | 1 | 4 | 7 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 3 | — | 1 | 2 | 7 |
| Depression | D003863 | — | F33.9 | — | 2 | — | 2 | 2 | 6 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 2 | — | 2 | 2 | 6 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 2 | 2 | 4 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | — | 1 | 1 | 4 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 10 | 12 | 1 | — | 5 | 25 |
| Addictive behavior | D016739 | EFO_0004347 | — | — | 3 | 1 | — | 7 | 10 |
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | 3 | — | 2 | 5 |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 1 | 1 | — | 1 | 2 |
| Drug therapy | D004358 | — | — | — | 1 | 1 | — | — | 1 |
| Parenting | D016487 | — | — | — | — | 1 | — | — | 1 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 1 |
| Glioma | D005910 | EFO_0000520 | — | — | — | 1 | — | — | 1 |
| Asthenia | D001247 | EFO_0007625 | R53.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | 1 | — | — | 4 | 15 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 2 | — | — | 5 | 7 |
| Narcolepsy | D009290 | HP_0030050 | G47.4 | 2 | 1 | — | — | 1 | 4 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | 2 | — | — | 1 | 3 |
| Traumatic stress disorders | D040921 | — | — | — | 2 | — | — | 1 | 3 |
| Anhedonia | D059445 | — | R45.84 | 1 | 1 | — | — | — | 2 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | 1 | — | — | 1 | 2 |
| Hiv seropositivity | D006679 | — | — | — | 1 | — | — | — | 1 |
| Pharmacogenomic testing | D000071185 | — | — | — | 1 | — | — | — | 1 |
| Gambling | D005715 | EFO_1001926 | F63.0 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | — | F17 | 1 | — | — | — | 3 | 4 |
| Drug misuse | D000076064 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | — | — | — | 3 | 3 |
| Hiv | D006678 | — | — | — | — | — | — | 2 | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | — | — | 2 | 2 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | — | 2 | 2 |
| Craving | D066249 | — | — | — | — | — | — | 2 | 2 |
| Personality disorders | D010554 | HP_0012075 | F60.6 | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
Show 46 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Amphetamine aspartate |
| INN | — |
| Description | 1-phenylpropan-2-amine is a primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group. |
| Classification | Small molecule |
| Drug class | CNS stimulant, anorectic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(N)Cc1ccccc1.NC(CC(=O)O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 156-34-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200377 |
| ChEBI ID | — |
| PubChem CID | 3007 |
| DrugBank | DB00182 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 54,201 documents
View more details
Safety
Black-box Warning
Black-box warning for: Adderall, Adderall xr, Dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate extended-release, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate tablets,cii, Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate, Mixed salts of a single entity amphetamine product, Mixed salts of a single-entity amphetamine product, Mydayis
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
48,646 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use